90 related articles for article (PubMed ID: 2501170)
21. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
[TBL] [Abstract][Full Text] [Related]
22. [Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
Kanamori H; Maruta A; Fukawa H; Harano H; Kodama F; Miyashita H; Matsuzaki M; Noguchi T; Murata T; Hashimoto Y
Rinsho Ketsueki; 1991 Feb; 32(2):108-14. PubMed ID: 2027236
[TBL] [Abstract][Full Text] [Related]
23. [Should patients over 65 years old with acute myeloid leukemia be treated with myelosuppressive chemotherapy?].
Spataro V; Cometta A; Glauser MP; Schapira M; Grob JP
Schweiz Med Wochenschr; 1995 Mar; 125(9):429-32. PubMed ID: 7892571
[TBL] [Abstract][Full Text] [Related]
24. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
25. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
Sperr WR; Piribauer M; Wimazal F; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Knöbl P; Jäger U; Lechner K; Valent P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3965-71. PubMed ID: 15217926
[TBL] [Abstract][Full Text] [Related]
26. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
27. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
Ruutu T; Koivunen E; Nousiainen T; Pelliniemi TT; Almqvist A; Anttila P; Jantunen E; Koistinen P; Koponen A; Mikkola M; Oksanen K; Pulli T; Remes K; Sarkkinen R; Silvennoinen R; Timonen T; Vanhatalo S; Elonen E;
Eur J Haematol; 2004 Jan; 72(1):38-44. PubMed ID: 14962261
[TBL] [Abstract][Full Text] [Related]
28. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
29. High doses of ara-C and m-AMSA in the treatment of refractory acute non lymphocytic leukemia.
Latagliata R; Petti MC; Spiriti MA; Meloni G; Sgadari C; Torromeo C; Vegna ML; Mandelli F
Haematologica; 1990; 75(3):249-51. PubMed ID: 2227622
[TBL] [Abstract][Full Text] [Related]
30. [Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Nagata K; Abe Y; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
Gan To Kagaku Ryoho; 1994 Feb; 21(2):231-6. PubMed ID: 8311494
[TBL] [Abstract][Full Text] [Related]
31. [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
Gan To Kagaku Ryoho; 1989 May; 16(5):2019-23. PubMed ID: 2730091
[TBL] [Abstract][Full Text] [Related]
32. Outcome of acute myeloid leukaemia in adults: a retrospective analysis.
Saikia TK; Bakshi A; Bhagwat R; Tawde S; Nair R; Nair CN; Parikh PM
Natl Med J India; 2005; 18(1):12-5. PubMed ID: 15835484
[TBL] [Abstract][Full Text] [Related]
33. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
34. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
[TBL] [Abstract][Full Text] [Related]
36. [A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
Lou FD; Zhou Q; Meng FY
Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):146-8, 187. PubMed ID: 1395925
[TBL] [Abstract][Full Text] [Related]
37. Progress and survival factors in acute non lymphocytic leukemia. A 15 year analysis.
Friedman S; Cowan DH; Nabholtz JM; Pinkerton PH; Senn JS
Nouv Rev Fr Hematol (1978); 1992; 34(3):233-7. PubMed ID: 1408734
[TBL] [Abstract][Full Text] [Related]
38. [DCTP(II) combination chemotherapy of adult acute nonlymphocytic leukemia].
Kobayashi T; Ogawa M; Kuraishi Y; Nagata T; Aiba K; Nakamura T; Usui N; Yamazaki H; Ichiba K; Isogai Y
Nihon Ketsueki Gakkai Zasshi; 1988 Aug; 51(5):855-63. PubMed ID: 3206983
[No Abstract] [Full Text] [Related]
39. [Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].
Bian SG; Hao YS; Wang ZC
Zhonghua Nei Ke Za Zhi; 1990 Jan; 29(1):22-5, 60. PubMed ID: 2401166
[TBL] [Abstract][Full Text] [Related]
40. Aclacinomycin, cytosine arabinoside and thioguanine in relapsed or resistant acute myeloid leukemia.
Neri A; Comis M; Brugiatelli M; Martino B; Ronco F
Haematologica; 1989; 74(1):113-4. PubMed ID: 2498174
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
